Beyond analysts' top -and-bottom-line estimates for Alnylam (ALNY), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ...

2025 Combined Net Product Revenue & Non-GAAP Operating Income Guidance Alnylam announced today full year 2025 combined net product revenue guidance for ONPATTRO, AMVUTTRA (PN & CM**), GIVLAARI and ...

The FDA has approved the first ever RNA interference drug – Alnylam’s Onpattro (patisiran) for the nerve damage caused by the rare disease hereditary transthyretin-mediated amyloidosis (hATTR ...

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has received an average recommendation of “Moderate Buy” from ...

Alnylam announced full year 2025 combined net product revenue guidance for ONPATTRO, AMVUTTRA (PN & CM), GIVLAARI and OXLUMO of $2.050 billion to $2.250 billion, representing combined full year ...

SG Americas Securities LLC cut its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 50.8% ...

Major players that have established their footprint in the Onpattro market include pharmaceutical giant Alnylam Pharmaceuticals Inc. Their operations have significantly influenced the market's ...

Alnylam’s Onpattro is a treatment for hereditary transthyretin-medicated amyloidosis (hATTR) in adults with stage 1 or stage 2 polyneuropathy. The rare and life-threatening disease is caused by ...

Alnylam Pharmaceuticals ALNY announced preliminary net product revenues for the fourth quarter and full-year 2024 for its approved products Onpattro (patisiran), Amvuttra (vutrisiran), Givlaari ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter ...